M&A Deal Summary |
|
|---|---|
| Date | 2010-10-08 |
| Target | Cypress Bioscience - Diagnostic Business |
| Sector | Life Science |
| Buyer(s) | Exagen |
| Sellers(s) | Cypress Bioscience |
| Deal Type | Divestiture |
| Deal Value | 8M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 2002 |
| Sector | Life Science |
| Employees | 174 |
| Revenue | 53M USD (2023) |
Exagen is a patient-focused, discovery-driven, CLIA-certified, CAP-accredited laboratory focused on providing physicians with products that address the significant unmet need for accurate and timely diagnosis, prognosis and monitoring of ARD/CTD. Exagen was founded in 2002 and is based in Vista, California.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| State (California) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2010) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
Cypress Bioscience, Inc. is committed to developing and commercializing pharmaceutical products and personalized medicine laboratory services that allow physicians to serve unmet medical needs.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| State (California) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2010) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2008-02-25 |
Proprius Pharmaceuticals
San Diego, California, United States Proprius Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and markets personalized medicine solutions in rheumatology and autoimmune diseases. |
Buy | $38M |
